NCT02811978View on ClinicalTrials.gov

Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

May 7, 2018

Study Completion Date

November 10, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.

DRUG

Dexamethasone

Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).

Trial Locations (10)

Unknown

Beijing

Chengdu

Chongqing

Fuzhou

Guangzhou

Nanjing

Shanghai

Suzhou

Tianjin

Wuhan

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02811978 - Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter